Cargando…
Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
Background: Ultrasound (US) is mostly used for diagnostic purpose but could be used for cancer treatments with a US intensity or frequency fitted to such a purpose. Prostate cancer (PC) has the highest prevalence in the urological field, but indications for immune checkpoint inhibitors (ICIs) for PC...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104877/ https://www.ncbi.nlm.nih.gov/pubmed/35566574 http://dx.doi.org/10.3390/jcm11092448 |
_version_ | 1784707902042275840 |
---|---|
author | Hayashi, Fuuka Shigemura, Katsumi Maeda, Koki Hiraoka, Aya Maeshige, Noriaki Ooya, Tooru Sung, Shian-Ying Yang, Yong-Ming Fujisawa, Masato |
author_facet | Hayashi, Fuuka Shigemura, Katsumi Maeda, Koki Hiraoka, Aya Maeshige, Noriaki Ooya, Tooru Sung, Shian-Ying Yang, Yong-Ming Fujisawa, Masato |
author_sort | Hayashi, Fuuka |
collection | PubMed |
description | Background: Ultrasound (US) is mostly used for diagnostic purpose but could be used for cancer treatments with a US intensity or frequency fitted to such a purpose. Prostate cancer (PC) has the highest prevalence in the urological field, but indications for immune checkpoint inhibitors (ICIs) for PC are limited to very few cases. In this study, we compared the antitumor effect of US irradiation alone with the combined use of US and ICIs in vitro and in vivo. Methods: PC cell line TRAMP-C2 cells were used in our experiments. TRAMP-C2 cells were irradiated with US with pulse repeated frequencies (PRF) of 1, 10, and 100 Hz. Cell proliferation was evaluated by MTS assay and apoptotic cells were analyzed using flow cytometry. To verify the antitumor effect of US irradiation on PC in vivo, we conducted animal experiments using mice. TRAMP-C2-bearing mice were irradiated with US with PRF of 10 and 100 Hz. Three weeks after the start of US irradiation, anti-PD-1 antibody was administered to the mice. Finally, mice were sacrificed and tumors were collected. Immunohistochemical (IHC) analyses were assessed for cleaved caspase-3 and CD3 in tumor cell extracts. Results: Cell proliferation assays showed that 1 and 10 Hz US significantly inhibited cell survival (p < 0.0001). In addition, US irradiation induced apoptosis at 1, 10, and 100 Hz (p = 0.0129, p = 0.0150, and p = 0.0017, respectively). In animal experiments, a significant tumor growth inhibitory effect was observed at 10 and 100 Hz, and 100 Hz + ICIs (p < 0.05, respectively). Hematoxylin–eosin (H–E) staining showed a significant increase in the necrotic area of the tumor at 100 Hz and 100 Hz + ICIs (p < 0.05, respectively). In addition, under IHC staining the expression level of cleaved caspase-3 and the number of CD3-positive cells increased at 100 Hz (p < 0.05, respectively). Conclusion: US irradiation induced apoptosis in cells and reduced cell viability. In vivo tumor growth was suppressed by combined treatment with US irradiation and ICIs. Further research on immune system activation will lead to less invasive and more efficient treatments for PC. |
format | Online Article Text |
id | pubmed-9104877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91048772022-05-14 Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer Hayashi, Fuuka Shigemura, Katsumi Maeda, Koki Hiraoka, Aya Maeshige, Noriaki Ooya, Tooru Sung, Shian-Ying Yang, Yong-Ming Fujisawa, Masato J Clin Med Article Background: Ultrasound (US) is mostly used for diagnostic purpose but could be used for cancer treatments with a US intensity or frequency fitted to such a purpose. Prostate cancer (PC) has the highest prevalence in the urological field, but indications for immune checkpoint inhibitors (ICIs) for PC are limited to very few cases. In this study, we compared the antitumor effect of US irradiation alone with the combined use of US and ICIs in vitro and in vivo. Methods: PC cell line TRAMP-C2 cells were used in our experiments. TRAMP-C2 cells were irradiated with US with pulse repeated frequencies (PRF) of 1, 10, and 100 Hz. Cell proliferation was evaluated by MTS assay and apoptotic cells were analyzed using flow cytometry. To verify the antitumor effect of US irradiation on PC in vivo, we conducted animal experiments using mice. TRAMP-C2-bearing mice were irradiated with US with PRF of 10 and 100 Hz. Three weeks after the start of US irradiation, anti-PD-1 antibody was administered to the mice. Finally, mice were sacrificed and tumors were collected. Immunohistochemical (IHC) analyses were assessed for cleaved caspase-3 and CD3 in tumor cell extracts. Results: Cell proliferation assays showed that 1 and 10 Hz US significantly inhibited cell survival (p < 0.0001). In addition, US irradiation induced apoptosis at 1, 10, and 100 Hz (p = 0.0129, p = 0.0150, and p = 0.0017, respectively). In animal experiments, a significant tumor growth inhibitory effect was observed at 10 and 100 Hz, and 100 Hz + ICIs (p < 0.05, respectively). Hematoxylin–eosin (H–E) staining showed a significant increase in the necrotic area of the tumor at 100 Hz and 100 Hz + ICIs (p < 0.05, respectively). In addition, under IHC staining the expression level of cleaved caspase-3 and the number of CD3-positive cells increased at 100 Hz (p < 0.05, respectively). Conclusion: US irradiation induced apoptosis in cells and reduced cell viability. In vivo tumor growth was suppressed by combined treatment with US irradiation and ICIs. Further research on immune system activation will lead to less invasive and more efficient treatments for PC. MDPI 2022-04-27 /pmc/articles/PMC9104877/ /pubmed/35566574 http://dx.doi.org/10.3390/jcm11092448 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hayashi, Fuuka Shigemura, Katsumi Maeda, Koki Hiraoka, Aya Maeshige, Noriaki Ooya, Tooru Sung, Shian-Ying Yang, Yong-Ming Fujisawa, Masato Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer |
title | Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer |
title_full | Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer |
title_fullStr | Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer |
title_full_unstemmed | Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer |
title_short | Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer |
title_sort | combined treatment with ultrasound and immune checkpoint inhibitors for prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104877/ https://www.ncbi.nlm.nih.gov/pubmed/35566574 http://dx.doi.org/10.3390/jcm11092448 |
work_keys_str_mv | AT hayashifuuka combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer AT shigemurakatsumi combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer AT maedakoki combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer AT hiraokaaya combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer AT maeshigenoriaki combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer AT ooyatooru combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer AT sungshianying combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer AT yangyongming combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer AT fujisawamasato combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer |